Insider Transactions in Q2 2023 at Akoya Biosciences, Inc. (AKYA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2023
|
Thomas A. Raffin Director |
BUY
Open market or private purchase
|
Indirect |
2,020,000
+9.4%
|
$10,100,000
$5.0 P/Share
|
|
Jun 12
2023
|
Robert G Shepler Director |
BUY
Open market or private purchase
|
Indirect |
120,000
+24.51%
|
$600,000
$5.0 P/Share
|
|
Jun 12
2023
|
Matthew Winkler Director |
BUY
Open market or private purchase
|
Direct |
203,388
+17.12%
|
$1,016,940
$5.0 P/Share
|
|
Jun 12
2023
|
Scott Mendel Director |
BUY
Open market or private purchase
|
Direct |
20,000
+41.24%
|
$100,000
$5.0 P/Share
|
|
Jun 12
2023
|
Goldman Myla Lai Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$100,000
$5.0 P/Share
|
|
Jun 12
2023
|
John Frederick Ek CFO |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$100,000
$5.0 P/Share
|
|
Jun 06
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-3.17%
|
$25,000
$5.71 P/Share
|
|
Jun 06
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.08%
|
$0
$0.3 P/Share
|